ArticlePloS one2025
Establishing a non-viral transfection system for fibroblasts using branched polyethylenimine.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enhanced survival of spiral ganglion neurons (SGN) could improve hearing in patients with cochlear implants. Supplying these cells with growth factors like brain-derived neurotropic factor (BDNF) has been shown to improve cell survival and vitality. Direct applications of BDNF, e.g., via integrated drug-delivering cannula, elevate the surgical risks, as well as the probability of infections. Therefore, in vivo production of BDNF by on-site transfection of cells with plasmid DNA coding for BDNF might be an option. Polyethylenimine (PEI) was chosen as a non-viral transfection reagent, due to its comparatively low cytotoxicity, ease of preparation and use. NIH/3T3 fibroblasts were used as model cells for fibroblast transfection that could be transferred to cochlear implants. Branched 25 kDa PEI was diluted in PBS and mixed in different ratios with two different plasmids coding for BDNF and tdTomato simultaneously. Particle size and zeta potential were determined, and cell metabolic activity was measured using MTT. Transfection efficiency was determined by counting cells with and without transfection-induced fluorescence. Complexes of DNA and PEI were mostly larger than DNA and PEI molecules alone. In addition, complexation of DNA with PEI altered the surface charge of the particles. The cell metabolic activity test confirmed cytocompatibility for almost all tested complexes of DNA and PEI. Plasmid A, which was based on a lentiviral vector backbone, resulted in a very low transfection efficiency of 0.4%, whereas with plasmid B, which was based on pUC19, a transfection efficiency of about 9% was achieved. Size and zeta potential indicate the formation of complexes with both plasmids. Transfection efficacy appears to be dependent on the size of the DNA molecule used. With successful transformation of nearly 10% efficiency and a comparatively low cytotoxicity, the proposed transfection system using plasmid B may be used for further experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.